Literature DB >> 311712

Adverse reactions to rifampicin.

D J Girling, K L Hitze.   

Abstract

This summary of adverse reactions to rifampicin has been prepared with the intention that it will be made available to all those involved in the administration of rifampicin in tuberculosis and leprosy control programmes. The reactions covered comprise those to both daily and intermittent administration, namely cutaneous and gastrointestinal reactions, hepatitis, and thrombocytopenic purpura, and those to intermittent administration only, namely "flu" syndrome, shock, shortness of breath, haemolytic anaemia, and renal failure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 311712      PMCID: PMC2395744     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  1 in total

Review 1.  Adverse reactions to rifampicin in antituberculosis regimens.

Authors:  D J Girling
Journal:  J Antimicrob Chemother       Date:  1977-03       Impact factor: 5.790

  1 in total
  7 in total

Review 1.  Pruritus associated with cholestasis. A review of pathogenesis and management.

Authors:  M Khandelwal; P F Malet
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

2.  Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide.

Authors:  Joo-Hee Kim; Jun-Il Moon; Jeong Eun Kim; Gil-Soon Choi; Hae-Sim Park; Young-Min Ye; Hyunee Yim
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

Review 3.  Age-related changes in the manifestations of tuberculosis. Implications for drug therapy.

Authors:  S Umeki
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

4.  Treatment of pruritus of primary biliary cirrhosis with rifampin.

Authors:  A Podesta; P Lopez; R Terg; F Villamil; D Flores; R Mastai; C B Udaondo; J P Companc
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

5.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 6.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

7.  An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.

Authors:  Liesbeth F Mieras; Anna T Taal; Wim H van Brakel; Emmanuelle Cambau; Paul R Saunderson; W Cairns S Smith; Cita Rosita S Prakoeswa; Linda Astari; David M Scollard; Dejair Caitano do Nascimento; Jacques Grosset; Hemanta K Kar; Shinzo Izumi; Laura Gillini; Marcos C L Virmond; Marieke G G Sturkenboom
Journal:  BMC Infect Dis       Date:  2018-10-05       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.